(NVKP-16-1-2016-0017 National Heart Program) Támogató: NKFIH
(FK 134751) Támogató: OTKA
(2018-1.3.1-VKE-2018-00024)
(K_21-139105) Támogató: NKFIA
(ANN 107803)
(105555) Támogató: OTKA
(RRF-2.3.1-21-2022-00003)
(2019-1.1.1-PIACI-KFI-2019-00367)
(2020-1.1.5-GYORSÍTÓSÁV-2021-00011)
(UNKP-20-5)
(ÚNKP-23-4-II-SE-34)
(János Bolyai Research Scholarship)
Cardioprotective miRNAs (protectomiRs) are promising therapeutic tools. Here, we aimed
to identify protectomiRs in a translational porcine model of acute myocardial infarction
(AMI) and to validate their cardiocytoprotective effect.Experimental
ApproachProtectomiR candidates were selected after systematic
analysis of miRNA expression changes in cardiac tissue samples from a closed‐chest
AMI model in pigs subjected to sham operation, AMI and ischaemic preconditioning,
postconditioning or remote preconditioning, respectively. Cross‐species orthologue
protectomiR candidates were validated in simulated ischaemia–reperfusion injury (sI/R)
model of isolated rat ocardiomyocytes and in human AC16 cells as well. For miR‐450a,
we performed target prediction and analysed the potential mechanisms of action by
GO enrichment and KEGG pathway analysis.Key
ResultsOut of the 220 detected miRNAs, four were up‐regulated
and 10 were down‐regulated due to all three conditionings versus AMI. MiR‐450a and
miR‐451 mimics at 25 nM were protective in rat cardiomyocytes, and miR‐450a showed
protection in human cardiomyocytes as well. MiR‐450a has 3987 predicted mRNA targets
in pigs, 4279 in rats and 8328 in humans. Of these, 607 genes are expressed in all
three species. A total of 421 common enriched GO terms were identified in all three
species, whereas KEGG pathway analysis revealed 13 common pathways.Conclusion
and ImplicationsThis is the first demonstration that miR‐450a
is associated with cardioprotection by ischaemic conditioning in a clinically relevant
porcine model and shows cardiocytoprotective effect in human cardiomyocytes, making
it a promising drug candidate. The mechanism of action of miR‐450a involves multiple
cardioprotective pathways.LINKED ARTICLESThis
article is part of a themed issue Non‐coding RNA Therapeutics. To view the other articles
in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc